Fidaxomicin in Clostridium difficile infection: added benefit not proven

Drug manufacturer did not submit studies on mild cases, and processed data in an unusable way for severe cases and recurrences

2013-07-02

(Press-News.org) The antibiotic fidaxomicin (trade name: Dificlir) has been approved in Germany since December 2011 for the treatment of adults who have diarrhoea caused by Clostridium difficile. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of fidaxomicin in comparison with current standard therapy. According to this, there is currently no proof of an added benefit. The manufacturer did not submit any studies on non-severe cases. It cited studies on severe courses of disease and recurrences, but did not process the results in a way that would make it possible to draw reliable overall conclusions on benefit and harm of fidaxomicin.

G-BA distinguished between three treatment situations

For this benefit assessment, the Federal Joint Committee (G-BA) distinguished between three treatment situations, and hence also specified different drugs as appropriate comparator therapy: in courses of the disease that were not severe, but required treatment, fidaxomicin was to be compared with the antibiotic metronidazole; in severe cases and in patients with recurrence, with vancomycin, another antibiotic.

No studies on comparison with metronidazole

Results of two randomized controlled trials (RCTs), both approval studies on fidaxomicin, were available for IQWiG's assessment (studies 101.1.C.003 and 101.1.C.004). In these studies, fidaxomicin was tested against the drug vancomycin in patients with all courses of the disease, i.e. including patients who were not severely affected.

Moreover, the manufacturer did not cite any additional studies for patients with non-severe course of the disease, in whom fidaxomicin was to be compared with metronidazole. So no data were available for this appropriate comparator therapy. Hence an added benefit for this subpopulation is not proven - however, this was not claimed by the manufacturer either.

Severe cases and recurrences: advantage of fidaxomicin in global cure

The two approval studies provided usable data on the outcome "global cure" for the two subpopulations "patients with severe course of disease" and "patients with recurrence". According to these studies, patients treated with fidaxomicin have better chances of cure than those treated with vancomycin. Here IQWiG derives a proof.

Data on side effects were not analysed appropriately

Side effects were also recorded in both approval studies. However, the manufacturer did not process these data in an appropriate way: The dossier contained information on severe adverse events only for the total study population, including non-severe cases. The manufacturer failed to analyse the data separately for the subpopulation defined by the G-BA. It cannot be excluded that, in a severe course of disease and recurrences, severe side effects are more frequent under fidaxomicin treatment than under vancomycin treatment.

Overall, the pharmaceutical company did not provide sufficient proof in its dossier that the positive effects (global cure) outweigh the negative effects (side effects). Hence an added benefit of fidaxomicin is not proven also in comparison with vancomycin on the basis of the manufacturer's dossier.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on fidaxomicin.

The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book V and specific German-language information on the assessment of fidaxomicin.

### END

ELSE PRESS RELEASES FROM THIS DATE:

Abiraterone: Hint of considerable added benefit

2013-07-02

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether abiraterone offers an added benefit compared with the present standard therapy. ...

The ribosome -- a new target for antiprion medicines

2013-07-02

New research results from Uppsala University, Sweden, show that the key to treating neurodegenerative prion diseases such as mad cow disease and Creutzfeldt-Jakob disease may lie in the ribosome, the protein synthesis machinery of the cell. The results were recently published in the Journal of Biological Chemistry. Prion diseases are fatal neurodegenerative diseases caused by misfolding of prion proteins. Examples of prion diseases are scrapie in sheep, mad cow disease and Creutzfeldt-Jakob disease in human. What triggers misfolding of the prion proteins to the amyloid ...

Companies look at wrong things when using facebook to screen job applicants

2013-07-02

Employers are increasingly using Facebook to screen job applicants and weed out candidates they think have undesirable traits. But a new study from North Carolina State University shows that those companies may have a fundamental misunderstanding of online behavior and, as a result, may be eliminating desirable job candidates. Researchers tested 175 study participants to measure the personality traits that companies look for in job candidates, including conscientiousness, agreeableness and extraversion. The participants were then surveyed on their Facebook behavior, allowing ...

Corn yield prediction model uses simple measurements at a specific growth stage

2013-07-02

The ability to predict corn yields would benefit farmers as they plan the sale of their crops and biofuel industries as they plan their operations. A new study published in the July-August issue of Agronomy Journal describes a robust model that uses easily obtained measurements, such as plant morphology and precipitation, collected specifically at the silking growth stage of the plant. The new model could help both growers and industry maximize their profits and efficiency. Forecasting crop yield can be extremely useful for farmers. If they have an idea of the amount ...

New hardware design protects data in the cloud

2013-07-02

CAMBRIDGE, Mass -- Cloud computing -- outsourcing computational tasks over the Internet -- could give home-computer users unprecedented processing power and let small companies launch sophisticated Web services without building massive server farms. But it also raises privacy concerns. A bank of cloud servers could be running applications for 1,000 customers at once; unbeknownst to the hosting service, one of those applications might have no purpose other than spying on the other 999. Encryption could make cloud servers more secure. Only when the data is actually being ...

Are thoughts of death conducive to humor?

2013-07-02

Humor is an intrinsic part of human experience. It plays a role in every aspect of human existence, from day-to-day conversation to television shows. Yet little research has been conducted to date on the psychological function of humor. In human psychology, awareness of the impermanence of life is just as prevalent as humor. According to the Terror Management Theory, knowledge of one's own impermanence creates potentially disruptive existential anxiety, which the individual brings under control with two coping mechanisms, or anxiety buffers: rigid adherence to dominant ...

Flexing the Verification Muscle

2013-07-02

The logistics were impressive, the timeframe tight, the conditions tough. From 26 May to 7 June 2013, nearly 150 experts from 40 countries set up shop on a military training ground near Veszprém, Hungary, for a simulated search for evidence of a nuclear explosion. Fifteen trucks transported 120 tons of state-of-the-art equipment from the CTBTO's Vienna storage facility to the site, where a fully functioning base of operations was established. Welcome to the world of on-site inspections (OSI). An OSI, a Treaty-specified search of the suspect area to determine if ...

Music to a gambler's ears

2013-07-02

Winning sounds on slot machines make gambling more exciting, according to a new study by Mike Dixon and colleagues from the University of Waterloo in Canada. Moreover, their work shows that sounds also cause players to overestimate the number of times they won while playing on slot machines. The study is published online in Springer's Journal of Gambling Studies. Sound has always been an integral part of the slot machine playing experience. Since the early 1900s, players have been rewarded with a ringing bell every time they have a winning combination. Today's slot machines ...

Neighborhood residents with lowest incomes most likely to care about their communities

2013-07-02

COLUMBIA, Mo. – Some may assume that low-income residents of run-down, crime-ridden neighborhoods do not care about their communities. However, research from the University of Missouri suggests otherwise. Mansoo Yu, an assistant professor of social work and public health at MU, studied levels of community care and vigilance among residents living in high-crime, low-income areas. Community care and vigilance refer to individuals' desires to improve their communities, to take pride in their neighborhoods and to monitor and report unwelcome happenings, such as crimes, near ...

Joslin scientists find that salsalate lowers blood glucose in type 2 diabetes

2013-07-02

BOSTON – July 1, 2013 -- Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes. The scientists became interested in studying salsalate, an anti-inflammatory drug, after research conducted by Steven Shoelson, M.D., Ph.D., Head of the Section on Pathophysiology and Molecular Pharmacology and Professor of Medicine ...